Emerging Antibody Engineering Strategies and Applications for Immunotherapy of Cancer
A special issue of Antibodies (ISSN 2073-4468). This special issue belongs to the section "Antibody-Based Therapeutics".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 6252
Special Issue Editors
Interests: immunotherapy of cancer; bispecific antibodies; T cell bispecific antibodies
Special Issues, Collections and Topics in MDPI journals
Interests: B cell responses in cancer; antibody engineering and glycoengineering; IgE class of antibodies in cancer; antibody Fc-mediated functions in cancer; cancer immunology; cancer immunotherapy; antibody-drug conjugates; melanoma; ovarian cancer; breast cancer; allergo-oncology; ADCC; ADCP; macrophages; monocytes; NK cells
Special Issues, Collections and Topics in MDPI journals
Interests: immunotherapy; therapeutic antibodies; antibody isotypes; antibody engineering; T-cells; myeloid cells; NK cells; B cells; cancer immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the past decade, cancer immunotherapy has revolutionized the treatment of hematological and solid tumors, resulting in the approval of checkpoint inhibitory antibodies, CAR-T cell therapies, and T cells engaging bispecific antibodies. Despite this progress, the lack of response and/or relapse and subsequent resistance to immunotherapy remain major clinical challenges requiring the development of optimized therapeutic agents and novel principles for targeting cancer. For this purpose, the application of state-of-the-art antibody engineering continues to play a key role. This Special Issue is intended to cover recent progress and novel concepts in the engineering of innovative antibody-based immunotherapies, including engineered checkpoint inhibitors, bispecific antibodies, immunocytokines, next-generation biologies, and engineered adoptive T cell therapy approaches.
Dr. Christian Klein
Prof. Dr. Sophia Karagiannis
Dr. Ann White
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mAb
- bsAb
- CPI
- TCE
- CPI
- CAR-T
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Related Special Issue
- Antibody Engineering for Cancer Immunotherapy in Antibodies (11 articles)
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: NK cytotoxicity displayed by NK-92 cell lines expressing combinations of two allelic variants for FCGR3
Author: Seebach
Highlights: • Eight NK-92 cell lines, each with specific FCGR3A SNP combinations, exhibited robust ADCC against diverse targets, with differences given by effector, antigen, and target cell array.
• The data suggest the FcγRIIIa/CD16's involvement in direct NK cytotoxicity.
• Implications for designing adoptive cancer immunotherapy with NK cells and tumor antigen-directed mAbs arise from these findings.